Featured

$PSTI Advances Towards U.S. Clinical Trial in PLX-R18 & Announces Principal Investigator

Pluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator Dr. Hillard Lazarus of Case Western Reserve University will be the Principal Investigator of the trial The...

Featured

$PSTI Receives Positive Feedback from FDA; Gears Up For Phase III Trials

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia   -CLI is a severe unmet medical need whose treatment addresses a $12 billion...

Featured #Stock Picks 2016

Our New Alert: Pluristem’s ($PSTI) Stroke of Genius – Fundamentally Changing the Way We Treat Disease

The phrase “Stroke of Genius” is unfortunately a hackneyed expression these days. The concept it conveys is a fundamental paradigm shift achieved through the recognition and exploitation of simplicity....

Featured #Stock Picks 2016

$MDVX Announces DenerveX Pre-Production Milestone

Medovex Corporation Announces DenerveX System Pre-Production Milestone With Extensive Live Tissue Model ATLANTA, GA--(Marketwired - Jun 6, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical...

Featured

$MDVX Receives Positive Lab Test Results

Medovex Corporation Receives Positive Final Laboratory Test Results Report ATLANTA, GA--(Marketwired - Jun 2, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today...

Featured #Markets

Biotech Firms are Solely Responsible for this Year’s IPO’s

Thursday February 11th brought about the trading introduction of two now public companies, bringing the total number of IPO’s on the year to four. However, last Thursday may be a sign of a new Initial...

Featured #Editorials

Biotech Analysts: Clear Opportunities In Biotechnology Stocks

While it’s no secret that Martin Shkreli gave a black eye to biotech stocks late last year, the wounds are starting to heal after January’s biotechnology market correction. J.P. Morgan analysts say that...